Literature DB >> 6280623

Oral converting enzyme inhibitor in malignant hypertension.

W Griswold, R McNeal, D O'Connor, V Reznik, S Mendoza.   

Abstract

Malignant hypertension, which developed in a 9-year-old boy after an episode of haemolytic uraemic syndrome, could not be controlled with antihypertensive agents. However, treatment with oral converting enzyme inhibitor (captopril) was effective in controlling the blood pressure and it averted bilateral nephrectomy. No adverse effects from the drug were noted.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6280623      PMCID： PMC1627604          DOI： 10.1136/adc.57.3.235

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  7 in total

1.  Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man.

Authors:  H Gavras; H R Brunner; G A Turini; G R Kershaw; C P Tifft; S Cuttelod; I Gavras; R A Vukovich; D N McKinstry
Journal:  N Engl J Med       Date:  1978-05-04       Impact factor: 91.245

2.  Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients.

Authors:  H R Brunner; H Gavras; B Waeber; G R Kershaw; G A Turini; R A Vukovich; D N McKinstry; I Gavras
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

3.  Minoxidil--an alternative to nephrectomy for refractory hypertension.

Authors:  W A Pettinger; H C Mitchell
Journal:  N Engl J Med       Date:  1973-07-26       Impact factor: 91.245

4.  Negative saralasin response in correctable renovascular hypertension.

Authors:  E B Trainin; V R Lala; G Gomez-Leon; T W AvRuskin
Journal:  J Pediatr       Date:  1978-09       Impact factor: 4.406

5.  Increased glomerular filtration rate after converting-enzyme inhibition in essential hypertension.

Authors:  N K Hollenberg; S L Swartz; D R Passan; G H Williams
Journal:  N Engl J Med       Date:  1979-07-05       Impact factor: 91.245

6.  Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.

Authors:  M A Ondetti; B Rubin; D W Cushman
Journal:  Science       Date:  1977-04-22       Impact factor: 47.728

7.  A specific orally active inhibitor of angiotensin-converting enzyme in man.

Authors:  R K Ferguson; G A Turini; H R Brunner; H Gavras; D N McKinstry
Journal:  Lancet       Date:  1977-04-09       Impact factor: 79.321
  7 in total
  3 in total

1.  Captopril in severe childhood hypertension--reversible anaemia with high dosage.

Authors:  H A Verhaaren; J Vande Walle; A Devloo-Blancquaert
Journal:  Eur J Pediatr       Date:  1986-04       Impact factor: 3.183

2.  Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome.

Authors:  Maria Van Dyck; Willem Proesmans
Journal:  Pediatr Nephrol       Date:  2004-04-03       Impact factor: 3.714

3.  Management of hypertensive emergencies.

Authors:  J E Deal; T M Barratt; M J Dillon
Journal:  Arch Dis Child       Date:  1992-09       Impact factor: 3.791
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.